↓ Skip to main content

Polyglutamine Disorders

Overview of attention for book
Cover of 'Polyglutamine Disorders'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Clinical Features of Huntington’s Disease
  3. Altmetric Badge
    Chapter 2 Genetic Rodent Models of Huntington Disease
  4. Altmetric Badge
    Chapter 3 Mitochondrial Dysfunction in Huntington’s Disease
  5. Altmetric Badge
    Chapter 4 RNA Related Pathology in Huntington’s Disease
  6. Altmetric Badge
    Chapter 5 X-Linked Spinal and Bulbar Muscular Atrophy: From Clinical Genetic Features and Molecular Pathology to Mechanisms Underlying Disease Toxicity
  7. Altmetric Badge
    Chapter 6 Spinocerebellar Ataxia Type 1: Molecular Mechanisms of Neurodegeneration and Preclinical Studies
  8. Altmetric Badge
    Chapter 7 Spinocerebellum Ataxia Type 6: Molecular Mechanisms and Calcium Channel Genetics
  9. Altmetric Badge
    Chapter 8 Spinocerebellar Ataxia Type 2
  10. Altmetric Badge
    Chapter 9 Molecular Mechanisms and Therapeutic Strategies in Spinocerebellar Ataxia Type 7
  11. Altmetric Badge
    Chapter 10 Spinocerebellar Ataxia Type 17 (SCA17)
  12. Altmetric Badge
    Chapter 11 The Neuropathology of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease
  13. Altmetric Badge
    Chapter 12 Origins and Spread of Machado-Joseph Disease Ancestral Mutations Events
  14. Altmetric Badge
    Chapter 13 Clinical Features of Machado-Joseph Disease
  15. Altmetric Badge
    Chapter 14 Polyglutamine-Independent Features in Ataxin-3 Aggregation and Pathogenesis of Machado-Joseph Disease
  16. Altmetric Badge
    Chapter 15 Animal Models of Machado-Joseph Disease
  17. Altmetric Badge
    Chapter 16 Towards the Identification of Molecular Biomarkers of Spinocerebellar Ataxia Type 3 (SCA3)/Machado-Joseph Disease (MJD)
  18. Altmetric Badge
    Chapter 17 Planning Future Clinical Trials for Machado-Joseph Disease
  19. Altmetric Badge
    Chapter 18 Molecular Mechanisms and Cellular Pathways Implicated in Machado-Joseph Disease Pathogenesis
  20. Altmetric Badge
    Chapter 19 Pharmacological Therapies for Machado-Joseph Disease
  21. Altmetric Badge
    Chapter 20 Gene Therapies for Polyglutamine Diseases
  22. Altmetric Badge
    Chapter 21 Stem Cell-Based Therapies for Polyglutamine Diseases
Attention for Chapter 9: Molecular Mechanisms and Therapeutic Strategies in Spinocerebellar Ataxia Type 7
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
5 X users

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Molecular Mechanisms and Therapeutic Strategies in Spinocerebellar Ataxia Type 7
Chapter number 9
Book title
Polyglutamine Disorders
Published in
Advances in experimental medicine and biology, January 2018
DOI 10.1007/978-3-319-71779-1_9
Pubmed ID
Book ISBNs
978-3-31-971778-4, 978-3-31-971779-1
Authors

Alice Karam, Yvon Trottier, Karam, Alice, Trottier, Yvon

Abstract

Spinocerebellar Ataxia type 7 (SCA7, OMIM # 164500) is an autosomal dominant neurodegenerative disorder characterized by adult onset of progressive cerebellar ataxia and blindness. SCA7 is part of the large family of autosomal dominant cerebellar ataxias (ADCAs), and was estimated to account for 1-11.7% of ADCAs in diverse populations. The frequency of SCA7 is higher where local founder effects were observed as in Scandinavia, Korea, South Africa and Mexico. SCA7 is pathomechanistically related to the group of CAG/polyglutamine (polyQ) expansion disorders, which includes other SCAs (1-3, 6 and 17), Huntington's disease, spinal bulbar muscular atrophy and dentatorubro pallidoluysian atrophy. Two distinctive characteristics of SCA7 are the strong anticipation by which earlier onset and more severe symptoms are observed in successive generations of affected families, and the loss of visual acuity due to cone-rod dystrophy of the retina. The pathology is caused by an unstable CAG repeat expansion coding for a polyQ stretch in Ataxin-7 (ATXN7). PolyQ expansion in ATXN7 confers toxic properties and leads to selective neuronal degeneration in the cerebellum, the brain stem and the retina. Herein, we summarize the genetic, clinical and pathological features of SCA7 and review our current knowledge of pathomechanisms and preclinical studies.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 46 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 17%
Student > Master 7 15%
Researcher 4 9%
Student > Ph. D. Student 4 9%
Student > Postgraduate 3 7%
Other 7 15%
Unknown 13 28%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 12 26%
Medicine and Dentistry 7 15%
Neuroscience 5 11%
Agricultural and Biological Sciences 3 7%
Arts and Humanities 2 4%
Other 6 13%
Unknown 11 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2018.
All research outputs
#7,546,261
of 23,023,224 outputs
Outputs from Advances in experimental medicine and biology
#1,233
of 4,964 outputs
Outputs of similar age
#153,700
of 442,364 outputs
Outputs of similar age from Advances in experimental medicine and biology
#43
of 237 outputs
Altmetric has tracked 23,023,224 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,964 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,364 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 237 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.